Your session is about to expire
← Back to Search
Ibrutinib for Chronic Lymphocytic Leukemia (MERIT Trial)
MERIT Trial Summary
This trial studies the side effects and effectiveness of ibrutinib in treating patients with CLL who responded to initial treatment, but have residual disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
MERIT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMERIT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 201 Patients • NCT03053440MERIT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am of childbearing age and do not plan to use birth control.I haven't used any experimental drugs in the last 28 days, except for low dose prednisone.You have other health conditions that could make it unsafe for you to take ibrutinib, such as HIV infection or bleeding disorders.I have had more than one treatment for my CLL symptoms.I have been cancer-free for over 3 years, except for non-melanoma skin cancer or cervical carcinoma in-situ.I am MRD- after initial treatment and my lymph nodes are smaller than 3.5 cm.I've completed at least 2 cycles of initial treatment for CLL and responded to it, but haven't had ibrutinib.I have a type of leukemia and still have some cancer cells despite treatment.I need treatment with strong medication that affects liver enzymes.My leukemia is confirmed as B-CLL by specific blood tests.I stopped my first treatment for B-CLL between 56 and 365 days ago.I have severe liver problems.I can follow the study schedule and am willing to give samples for research.I am currently taking warfarin or similar blood thinners.I am currently breastfeeding.My condition has worsened or returned after treatment.I have not had major surgery in the last 4 weeks.I have active infectious hepatitis.I can take care of myself and am up and about more than half of my waking hours.
- Group 1: Treatment (ibrutinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is registration open for this particular experiment?
"Regrettably, this study is not open to participants at the moment. Although first posted on February 8th 2016 and updated as recently as March 24th 2022, it needs to be reopened before recruitment can take place again. Alternately, if you are seeking other trials there are 1552 studies enrolling individuals with lymphoid leukemia and 155 clinical experiments actively looking for candidates taking part in Ibrutinib therapy."
What is the current enrollment capacity for this clinical investigation?
"This medical study is no longer recruiting patients. After being posted on February 8th 2016 and last updated March 24th 2022, this trial has reached its capacity. Alternately, there are presently 1552 research studies that require participants for lymphoid leukemia and 155 trials seeking candidates to test Ibrutinib's efficacy."
What potential hazards should patients be aware of when taking Ibrutinib?
"Based on the available evidence, our team at Power has given Ibrutinib a safety rating of 2. This is because it's in Phase 2 trials and there are some studies suggesting its safety but none that confirm its efficacy."
Share this study with friends
Copy Link
Messenger